The classic strengths of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) stood out in the company’s second quarter report published last Thursday. Teva continues to be creative and combative. Despite difficult market conditions and problems with certain drugs, the company continues to cope with the range of markets and products in which it operates, by increasing efforts around existing products, and changing pricing methods and distribution patterns as well as marketing and financing activities.
Even in a period when many factors are working against the company, Teva has still managed somehow to reach the analysts’ estimates, and maintains growth from quarter to quarter in both profitability and revenue, even if this is mainly through its acquisitions.
When Teva CEO Dr. Jeremy Levin assumed the helm earlier this year, these were the areas about which the market was less certain. It was known that Levin was a strategist and highly capable business development man, but what about the basic
Meanwhile, it appears that Levin has so far successfully passed the basic field test. He has not hesitated in taking significant steps in areas such as logistics, pricing and manufacturing. In order to support the company’s activities in these fields, Levin has also brought in a backup player in the shape of Dr. Carlo De Notaristefani as president and CEO of global operations, who previously served as VP operations at Bristol-Myers Squibb Inc. (NYSE: BMY), Levin’s old firm. De Notaristefani is known as a “cuts” man and Levin has already said that part of his strategy will be greater “budgetary discipline,” in a company that has never been known as wasteful…Read More>>